The immune effects of the IMiDs are well established and include increased interleukin (IL)-2 and interferon-γ production, T-cell proliferation, and natural killer (NK) and NK T-cell activation, counteracting the immune dysfunction effects caused by the development of MM and resulting in substantial antimyeloma activity, notably in combination with anti-CD38 and anti-SLAMF7 mAbs [56]. Here, CD38 is linked to Miyoshi myopathy.